KRAS and non-small cell lung carcinoma: An interesting question in the future will be whether patients with NSCLC might also benefit from HER3-DXd when they are simultaneously treated with immunotherapy or other molecular targeted agents (e.g., direct KRAS G12C, MEK or ALK inhibitors).